Press release
Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders
CB 2782-PEG patent protection extended until at least 2038 SOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"CB 2782-PEG patent protection extended until at least 2038\nSOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 10,954,501 B2 entitled “Nucleic Acid Encoding Modified Membrane Type Serine Protease 1 (MTSP-1) Polypeptides and Methods of Use.\" This patent expands the Company's portfolio of intellectual property covering its complement programs and protease medicines. The patent protects nucleic acids encoding modified proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, Catalyst's potential best-in-class treatment for dry AMD, currently licensed to Biogen. Further coverage of a broad range of additional uses in diseases mediated by complement activation provides protection until at least 2038. \"Building a strong patent intellectual property estate around our protease medicines and complement programs protects our ability to develop multiple assets and create long-term shareholder value,\" said Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences. \"We intend to continue to expand our IP as we develop our pipeline of protease medicines.\" About Catalyst Biosciences, the Protease Medicines companyCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a pre-clinical C3-degrader program licensed to Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency, and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development. Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the pro...